Evidence map›Paper›PMID 34901605›Full record

ArticleACS omega2021

Bispecific Aptamer Sensor toward T-Cell Leukemia Detection in the Tumor Microenvironment.

Natalie Boykoff, Lina Freage, Jared Lenn, Prabodhika Mallikaratchy

Abstract read
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Synthetic living materials in cancer biology.Nature reviews bioengineering · 2023
    Article
  4. Biomedical Diagnosis of Leukemia Using a Deep Learner Classifier.Computational intelligence and neuroscience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Natalie BoykoffPh.D. Programs in Chemistry and Biochemistry, CUNY Graduate Center, 365 Fifth Avenue, New York, New York 10016, United States.
Lina FreageDepartment of Chemistry, Lehman College, The City University of New York, 250 Bedford Park Blvd., West, Bronx, New York 10468, United States.
Jared LennThe Bronx High School of Science, 75 W 205th Street, Bronx, New York 10468, United States.
Prabodhika MallikaratchyDepartment of Chemistry, Lehman College, The City University of New York, 250 Bedford Park Blvd., West, Bronx, New York 10468, United States.ORCID https://orcid.org/0000-0002-6437-4613

Funding

Discovery and development of artificial nucleic acid ligands to probe cellular interactionsR35GM139336 · NIGMS · HERBERT H. LEHMAN COLLEGE · PI MALLIKARATCHY, PRABODHIKA · 2021 to 2025
$1.9M
Ligand Guided Selection of Aptamers against Human Leukemia and LymphomaSC1GM122648 · NIGMS · HERBERT H. LEHMAN COLLEGE · PI MALLIKARATCHY, PRABODHIKA · 2017 to 2020
$1.5M
NIGMS NIH HHS R35 GM139336NIGMS NIH HHS SC1 GM122648
6 · The paper itself

Abstract

The current detection methods of malignant cells are mainly based on the high expression levels of certain surface proteins on these cells. However, many of the same surface marker proteins are also expressed in normal cells. Growing evidence suggests that the molecular signatures of the tumor microenvironment (TME) are related to the biological state of a diseased cell. Exploiting the unique molecular signature of the TME, we have designed a molecular sensing agent consisting of a molecular switch that can sense the elevated concentration of a small molecule in the TME and promote precise recognition of a malignant cell. We accomplished this by designing and developing a bispecific aptamer that takes advantage of a high concentration of adenosine 5'-triphosphate in the TME. Thus, we report a prototype of a bispecific aptamer molecule, which serves as a dual detection platform and recognizes tumor cells only when a given metabolite concentration is elevated in the TME. This system overcomes hurdles in detecting tumor cells solely based on the elevated expression of cell surface markers, providing a universal platform for tumor targeting and sensing.

Identifiers

PMID34901605
PMCPMC8655784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.